Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation

    SBC: Deep Blue Medical Advances, Inc.            Topic: 300

    Abstract Two million laparotomies are performed annually in the U S with ventral hernia being a frequent complication in of patients The average cost patient for each hernia operation in the U S in was $ which amounts to $ billion annually The ten year ventral hernia recurrence rate is There are $ B in hernia meshes sold annually in the United States With ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. A Randomized Blinded Placebo Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell LMSC Therapy for Treating The Metabolic Syndrome

    SBC: Longeveron LLC            Topic: NIA

    The metabolic syndrome MetS is a cluster of factors that increases the risks for cardiovascular disease type diabetes mellitus and mortality and currently affects andgt of US adults MetS is associated with endothelial dysfunction decreased circulating endothelial progenitor cells EPCs and a pro inflammatory state We have made the exciting discovery that therapy with allogeneic me ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. AML MutationCounter a tool to detect residual and recurrent leukemia

    SBC: Asystbio Laboratories, LLC            Topic: 102

    Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Artificial neural networks for high performance fully automated particle tracking analysis even at low signal to noise regimes

    SBC: AI Tracking Solutions LLC            Topic: 400

    Abstract Particle tracking PT is a powerful biophysical tool for elucidating molecular interactions transport phenomena and rheological properties in complex biological environments Unfortunately PT remains a niche tool in life and physical sciences with a limited user base in large part due to significant time and technical constraints in extracting accurate time variant positional data fr ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Creation of animal models of mitochondrial DNA disease for translational research applications

    SBC: Enzerna Biosciences LLC            Topic: 400

    Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Delivery of pathogen trapping antibodies for vaginal protection

    SBC: MUCOMMUNE, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Despite immense efforts in behavioral interventions to promote safer sexual practices sexually transmitted infections STIs continue to be a pandemic worldwide Unfortunately there are no effective vaccines or microbicides for the majority of STIs A pathogen specific safe effective and discreet vaginal microbicide that does not require daily or sex associ ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Delivery of peptides for inducing voiding associated with neurological retention

    SBC: Dignify Therapeutics LLC            Topic: 106

    Abstract Neurological conditions such as multiple sclerosis Parkinson s disease dementia spina bifida diabetes stroke and spinal cord injury SCI can result in loss of voluntary voiding of urine and require intermittent bladder catheterization for voiding Catheter use is associated with increased incidence of health problems predominately repeated urinary tract infections sepsis ureth ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Developing a novel therapy for diabetic retinopathy

    SBC: Everglades Biopharma, LLC            Topic: W

    Project Summary Diabetic retinopathy DR is a leading cause of vision loss affecting about million people worldwide A major breakthrough in DR therapy is the recent approval of vascular endothelial growth factor VEGF inhibitors However anti VEGF therapy has limited efficacy with a number of side effects The critical barrier is how to identify other angiogenic targets for alternative or ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a New Carbohydrate based Anticoagulant Drug

    SBC: Glycan Therapeutics LLC            Topic: NHLBI

    Low molecular weight heparins LMWHs a commonly used anticoagulant drug in the hospitals are carbohydrate based molecules Heparin is isolated from porcine intestine through a long and unreliable supply chain LMWH is a depolymerized product of heparin A worldwide distribution of contaminated heparin in impacting the purity and safety of LMWHs was associated with deaths in the US Th ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies

    SBC: Gateway Bio, Inc.            Topic: NHLBI

    ABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government